Research from the drug company Moderna suggests its new mpox vaccine, based on mRNA technology, might be more effective than current vaccines.

After an mRNA vaccine for mpox achieved promising results in monkeys, researchers say it could have several advantages over existing vaccines – but cold storage requirements mean it will be hard to ro

The experimental mRNA shot, tested in macaques, generated a stronger immune response and dramatically reduced the number of mpox lesions in infected animals compared to Bavarian Nordic’s licensed vaccine,

Investigational mpox mRNA vaccine, developed by Moderna, reduces disease severity in primates compared to available vaccines.

In the new study, Alter and colleagues tested the Moderna mRNA vaccine against the older form of vaccine in a group of 18 macaque monkeys exposed to the mpox virus. Six of the primates received the older type of vaccine, six received the experimental Moderna mRNA vaccine, and six more monkeys were left unvaccinated.

An experimental Moderna mRNA vaccine for mpox has demonstrated greater effectiveness than current shots in reducing disease symptoms and duration, according to an animal study published in the journal Cell on Wednesday.

The vaccine manufacturer Moderna reported in the journal Cell that a messenger RNA-based mpox vaccine that it is developing was more protective than a vaccine made using the same platform as Bavarian Nordic’s Jynneos vaccine in a study in which non-human primates were vaccinated,